Latest Dabigatran Stories

The clot-busting medicine, tPA (tissue plasminogen activator), is safe to use in acute stroke patients already on the home blood thinner warfarin, according to researchers from Duke Clinical Research Institute (DCRI). This study helps allay previous concerns that tPA was too dangerous to use in patients on home anticoagulation and would lead to high risk for potentially fatal intracranial bleeding. "To date, we have no randomized trials or large cohort studies to guide us," says Ying Xian,...

(Ivanhoe Newswire) – Researchers from the Duke Clinical Research Institute have ruled the clot-busting drug tPA (tissue plasminogen activator) safe for acute stroke patients on the home blood thinner warfarin. The drug was previously thought to be too dangerous to use in patients on home anticoagulation for fear of a higher risk of fatal intracranial bleeding. "To date, we have no randomized trials or large cohort studies to guide us," Ying Xian, M.D., Ph.D., assistant professor of...

RIDGEFIELD, Conn., June 18, 2012 /PRNewswire/ -- A new retrospective sub-analysis of the RE-LY® trial suggested similar rates of peri-procedural bleeding and thromboembolic complications, such as a stroke or systemic embolism, in non-valvular atrial fibrillation (NVAF) patients undergoing a surgical or invasive procedure treated with Pradaxa® (dabigatran etexilate mesylate) capsules 150mg taken twice daily compared to warfarin. The peri-procedural period was defined in this...

RIDGEFIELD, Conn., June 6, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the Pradaxa® (dabigatran etexilate mesylate) capsules prescribing information has been updated to affirm that "PRADAXA 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin." The update to the "Clinical Studies" section is based on the results of the pivotal RE-LY® trial conducted in 18,000 patients with non-valvular atrial...

FORT WORTH, Texas, June 1, 2012 /PRNewswire/ -- A motion was filed on May 30, 2012 with the United States Judicial Panel on Multidistrict Litigation (JPML) petitioning for the creation of a coordinated federal MDL for all cases concerning the anticoagulant drug Pradaxa (dabigatran etexilate mesylate). The motion seeks to transfer pending cases and future claims relating to Pradaxa to the United States District Court for the Southern District of Illinois for consolidation. The United...

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org (PRWEB) May 25, 2012 The Pradaxa Resource Center, a patient advocacy group, is alerting patients affected by internal bleeding episodes after taking the drug Pradaxa that lawyers are investigating claims that the drug is defective. This comes as researchers have warned the drug may have higher rates of death or serious internal...

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org. Orlando, FL (PRWEB) May 11, 2012 The Pradaxa Resource Center, a patient advocacy group, is alerting patients taking the atrial fibrillation drug Pradaxa of research showing the drug may have higher rates of death or serious internal bleeding than the traditional blood thinner Coumadin. Some victims of Pradaxa bleeding have...

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org Orlando, FL (PRWEB) May 09, 2012 The Pradaxa Resource Center, a patient advocacy group, is alerting patients taking the atrial fibrillation drug Pradaxa that recent information has related the drug to serious or fatal internal bleeding, and several victims have already filed lawsuits for injury or death. If you have questions...

RIDGEFIELD, Conn., May 3, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of the GLORIA(TM)-AF Registry Program, the largest prospective observational study in non-valvular atrial fibrillation (NVAF) planned at this time. With a goal of enrolling 56,000 patients, the registry aims to understand the long-term use of antithrombotic treatments to reduce the risk of stroke in patients with NVAF. GLORIA-AF will follow newly-diagnosed...

RIDGEFIELD, Conn., April 18, 2012 /PRNewswire/ -- A new retrospective sub-analysis of the 18,113 patient RE-LY® trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa® (dabigatran etexilate mesylate) capsules 150mg taken twice daily compared with warfarin. Results of the sub-analysis recently were published online in Stroke: The Journal of the American Heart Association. Intracranial hemorrhage can be a devastating...